Poolbeg Pharma (LON:POLB) Given House Stock Rating at Shore Capital

Shore Capital reissued their house stock rating on shares of Poolbeg Pharma (LON:POLB) in a research report sent to investors on Wednesday morning, Marketbeat reports.

Poolbeg Pharma Trading Up 10.6%

LON:POLB opened at GBX 4.48 on Wednesday. The company’s 50-day moving average price is GBX 4.11 and its 200-day moving average price is GBX 3.69. The company has a market cap of £31.23 million, a P/E ratio of -3.93 and a beta of 2.11. Poolbeg Pharma has a twelve month low of GBX 2.25 and a twelve month high of GBX 5.50.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.